Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment.
Lengliné E, Peron J, Vanier A, Gueyffier F, Kouzan S, Dufour P, Guillot B, Blondon H, Clanet M, Cochat P, Degos F, Chevret S, Grande M, Putzolu J; Transparency Committee of the French National Authority for Health. Lengliné E, et al. Among authors: degos f. Lancet Oncol. 2021 Oct;22(10):e430-e434. doi: 10.1016/S1470-2045(21)00337-5. Lancet Oncol. 2021. PMID: 34592192 Review.
Incidence of liver abnormalities in Fanconi anemia patients.
Masserot-Lureau C, Adoui N, Degos F, de Bazelaire C, Soulier J, Chevret S, Socié G, Leblanc T. Masserot-Lureau C, et al. Among authors: degos f. Am J Hematol. 2012 May;87(5):547-9. doi: 10.1002/ajh.23153. Epub 2012 Apr 10. Am J Hematol. 2012. PMID: 22488129 Free article.
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.
Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P, Ollivier I, Vinel JP, Mathurin P, Bronowicki JP, Vilgrain V, N'Kontchou G, Beaugrand M, Chevret S; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Trinchet JC, et al. Among authors: degos f. Hepatology. 2011 Dec;54(6):1987-97. doi: 10.1002/hep.24545. Hepatology. 2011. PMID: 22144108 Clinical Trial.
Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group.
Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Degos F, et al. J Hepatol. 1998 Aug;29(2):224-32. doi: 10.1016/s0168-8278(98)80007-x. J Hepatol. 1998. PMID: 9722203 Clinical Trial.
Serum albumin and platelet count but not portal pressure are predictive of death in patients with Child-Pugh A hepatitis C virus-related cirrhosis.
Nahon P, Ganne-Carrié N, Degos F, Nahon K, Paries J, Grando V, Chaffaut C, Njapoum C, Christidis C, Trinchet JC, Chevret S, Beaugrand M. Nahon P, et al. Among authors: degos f. Gastroenterol Clin Biol. 2005 Apr;29(4):347-52. doi: 10.1016/s0399-8320(05)80779-1. Gastroenterol Clin Biol. 2005. PMID: 15864193 Free article.
[Hepatitis C infection: Therapeutic strategies].
Diatta T, Chavade D, Degos F, d'Andon A, Guillevin L. Diatta T, et al. Among authors: degos f. Presse Med. 2016 May;45(5):495-508. doi: 10.1016/j.lpm.2016.02.006. Epub 2016 Mar 19. Presse Med. 2016. PMID: 27006245 Review. French.
Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S, Balian A, Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Bailly F, Chaumet-Riffaud P, Emilie D. Naveau S, et al. Among authors: degos f. J Hepatol. 1999 Oct;31(4):612-7. doi: 10.1016/s0168-8278(99)80339-0. J Hepatol. 1999. PMID: 10551383 Clinical Trial.
173 results